Tobam Buys 4,953 Shares of United Therapeutics Corporation $UTHR

Tobam raised its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 183.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,646 shares of the biotechnology company’s stock after acquiring an additional 4,953 shares during the quarter. Tobam’s holdings in United Therapeutics were worth $3,205,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of UTHR. Norges Bank purchased a new position in United Therapeutics in the second quarter valued at approximately $136,453,000. Invesco Ltd. increased its position in United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after buying an additional 419,588 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after buying an additional 364,713 shares during the last quarter. Assetmark Inc. lifted its position in shares of United Therapeutics by 38.1% during the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after buying an additional 197,384 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of United Therapeutics during the 2nd quarter worth $55,746,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Down 0.5%

United Therapeutics stock opened at $473.66 on Monday. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99. The firm has a market capitalization of $20.40 billion, a PE ratio of 17.95, a price-to-earnings-growth ratio of 2.52 and a beta of 0.85. The firm’s 50 day simple moving average is $486.02 and its 200 day simple moving average is $434.55.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $474.65, for a total transaction of $10,679,625.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christopher Causey sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $510.00, for a total value of $510,000.00. Following the completion of the sale, the director directly owned 4,190 shares in the company, valued at approximately $2,136,900. The trade was a 19.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 454,714 shares of company stock valued at $219,909,558. Company insiders own 10.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. UBS Group boosted their price objective on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, Royal Bank Of Canada increased their target price on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.